Matthew Nigrelli Email

Director, Quality Systems & Compliance . Visterra

Current Roles

Employees:
149
Revenue:
$28.9M
About
Visterra discovers and develops novel drugs utilizing its proprietary platform based on the atomic interaction network analyses of proteins. The company's innovative technology platform enables a more in depth, three-dimensional structural understanding of proteins to (i) identify unique target epitopes and (ii) guide the design of novel drugs to effectively combat disease. The company has established proof-of-concept with its lead product candidate, VIS410, a monoclonal antibody which represents a significant advancement in the treatment and prevention of both seasonal and pandemic influenza. VIS410 is also an important validation of the broad potential of Visterra's technology platform. The company is building a proprietary pipeline of novel drugs targeting infectious diseases. Through a coalition of partners with a shared mission – including U.S. and non-U.S. governments, global foundations and pharmaceutical companies – Visterra is committed to providing safe and effective therapies to patients in both the developed and developing world.
Visterra Address
275 2nd Avenue
Waltham, MA
United States

Past Companies

Visterra Inc.Director, Quality Systems & Compliance
CRISPR TherapeuticsDirector, Supplier Quality Management
CRISPR TherapeuticsDirector, QA Compliance

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.